The France Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The France Journal.

Press releases published on September 30, 2026

Sep. 30, 2026

From Detection to Visual Confirmation: CHASING CanFish F2 Combines Sonar, Underwater Vision and AI

Indeterminate EIN Presswire

Sep. 30, 2026

Alice & Bob Demonstrates New Approach to Stabilising Cat Qubits with DC Voltage Bias

Indeterminate EIN Presswire

Sep. 30, 2026

Heimdal CEO: AI labs can choose their pace, defenders can't

Indeterminate EIN Presswire

Sep. 30, 2026

Vera Welcomes Trevor Tierney as Senior Manager, Advisory to Manage Workforce-Readiness Learning and Development

Indeterminate EIN Presswire

Sep. 30, 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Pete Blackshaw Launches The Answer Economy, a New Playbook for Brands in the AI Era

Indeterminate EIN Presswire

Sep. 30, 2026

Shandong Niudian: China Leading L6e Quadricycle Wvta Certified Germany

Indeterminate EIN Presswire

Sep. 30, 2026

Former U.S. NRC Commissioner and U.S. DOE Nuclear Chief William D. Magwood, IV to Join newcleo’s Board of Directors in January 2027

Indeterminate GlobeNewswire

Sep. 30, 2026

Sekoia Elevate macht autonome Cyberabwehr zur Realität: von Sicherheitsmeldungen zur Bewertung in 99 Sekunden

Indeterminate GlobeNewswire

Sep. 30, 2026

Sekoia Elevate brings autonomous cyber defense to life: from security data to verdict in 99 seconds

Indeterminate GlobeNewswire

Sep. 30, 2026

Sekoia Elevate hace realidad la ciberdefensa autónoma: de los datos de seguridad al veredicto en 99 segundos

Indeterminate GlobeNewswire

Sep. 30, 2026

Sekoia Elevate rende concreta la difesa informatica autonoma: dai dati di sicurezza al verdetto in 99 secondi

Indeterminate GlobeNewswire

Sep. 30, 2026

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire

Sep. 30, 2026

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study

Indeterminate GlobeNewswire